DEVELOPMENT OF METHODS FOR SCREENING PHARMACOLOGIC TREATMENTS OF SUBSTANCE ABUSE

药物滥用药物治疗筛查方法的开发

• 批准号: 3752865
• 负责人: K L PRESTON
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON DRUG ABUSE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3752865
• 关键词: cardiovascular function; cocaine; drug abuse chemotherapy; drug addiction; human subject; human therapy evaluation; opiate alkaloid; oral administration; pharmacokinetics; psychopharmacology; substance abuse related disorder

We have begun a program of research to develop a laboratory model of cocaine abuse using very low doses of oral cocaine, doses that produce measurable behavioral effects but minimal cardiovascular effects. The first protocol in this research program uses a drug discrimination procedure to explore the limits of human behavioral sensitivity to oral cocaine. Initially, subjects in this protocol are taught to distinguish 50 mg of oral cocaine from placebo using a drug discrimination procedure. Then subjects are exposed to 4 doses of oral cocaine (6.25 mg, 12.5 mg, 25 mg, and 50 mg) and placebo in random order across days to determine the lowest doses of cocaine that subjects can detect. Throughout all of these administrations the cardiovascular and self-reported mood effects of these cocaine doses are determined. The protocol is currently ongoing. Further studies are planned to study cocaine and opioid drug discrimination, cocaine and opioid self-administration studies, the pharmacodynamic and pharmacokinetic effects of coca tea, and a multiple-choice behavioral paradigm for screen medications.

我们已经开始了一项研究计划，开发一个实验室模型 可卡因滥用使用非常低剂量的口服可卡因，剂量产生 可测量的行为影响，但对心血管的影响最小。 这 该研究计划的第一个方案使用药物歧视 探索人类行为对口腔的敏感性极限的程序 可卡因。 最初，该协议中的受试者被教导区分 使用药物歧视程序从安慰剂中口服 50 毫克可卡因。 然后受试者暴露于 4 剂口服可卡因（6.25 毫克、12.5 毫克、 25 毫克和 50 毫克）和安慰剂在几天内随机排列以确定 受试者可以检测到的可卡因的最低剂量。 贯穿所有 这些给药对心血管和自我报告的情绪影响 这些可卡因剂量的确定。 该协议目前 正在进行中。 计划进一步研究可卡因和阿片类药物 歧视、可卡因和阿片类药物自我给药研究， 古柯茶的药效学和药代动力学作用，以及 筛选药物的多项选择行为范例。